Hematologic Malignancy
Myelodysplastic Syndrome Post Cytotoxic Therapy
CI-CAN-00003368Explore in graph →
Hematologic6 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003368Explore in graph →
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04726241 | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | recruiting | Phase 1 / Phase 2 | 960 | PedAL BCU, LLCOTHER |
| 5 |
| Aug 25, 2026 |
| clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2026source: clinicaltrials